Mechanisms of resistance to cisplatin

被引:740
作者
Kartalou, M
Essigmann, JM
机构
[1] MIT, Div Bioengn & Environm Hlth, Cambridge, MA 02139 USA
[2] MIT, Dept Chem, Cambridge, MA 02139 USA
关键词
cisplatin; drug resistance; DNA adducts; testicular cancer; ovarian cancer; nucleotide excision repair; recombinational repair; double strand break repair; mismatch reapir; polymerase beta; tolerance; replication bypass; apoptosis;
D O I
10.1016/S0027-5107(01)00141-5
中图分类号
Q81 [生物工程学(生物技术)]; Q93 [微生物学];
学科分类号
071005 ; 0836 ; 090102 ; 100705 ;
摘要
The use of cisplatin in cancer chemotherapy is Limited by acquired or intrinsic resistance of cells to the drug. Cisplatin enters the cells and its chloride ligands are replaced by water, forming aquated species that react with nucleophilic sites in cellular macromolecules. The presence of the cisplatin adducts in DNA is thought to trigger cell cycle arrest and apoptosis. Knowledge of the mechanism of action of cisplatin has improved our understanding of resistance. Decerased intracellular concentration due to decreased drug uptake, increased reflux or increased inactivation by sulfhydryl molecules such as glutathione can cause resistance to cisplatin. Incresed excision of the adducts from DNA by repair pathways or increased lesion bypass can also result in resistance. Finally, altered expression of regulatory proteins involved in signal transduction pathways that control the apoptotic pathway can also affect sensitivity to the drug. An improved understanding of the mechanisms of resistance operative in vivo has identified targets for intervention and may increase the utility of cisplatin for the treatment of cancer. (C) 2001 Elsevier Science B.V. All rights reserved.
引用
收藏
页码:23 / 43
页数:21
相关论文
共 237 条
[61]  
Ferry K. V., 1996, Proceedings of the American Association for Cancer Research Annual Meeting, V37, P365
[62]  
FICHTINGERSCHEPMAN AMJ, 1990, CANCER RES, V50, P7887
[63]  
FICHTINGERSCHEPMAN AMJ, 1987, CANCER RES, V47, P3000
[64]   ADDUCTS OF THE ANTITUMOR DRUG CIS-DIAMMINEDICHLOROPLATINUM(II) WITH DNA - FORMATION, IDENTIFICATION, AND QUANTITATION [J].
FICHTINGERSCHEPMAN, AMJ ;
VANDERVEER, JL ;
DENHARTOG, JHJ ;
LOHMAN, PHM ;
REEDIJK, J .
BIOCHEMISTRY, 1985, 24 (03) :707-713
[65]  
Fink D, 1996, CANCER RES, V56, P4881
[66]   Expression of the DNA mismatch repair proteins hMLH1 and hPMS2 in normal human tissues [J].
Fink, D ;
Nebel, S ;
Aebi, S ;
Zheng, H ;
Kim, HK ;
Christen, RD ;
Howell, SB .
BRITISH JOURNAL OF CANCER, 1997, 76 (07) :890-893
[67]  
Fink D, 1997, CANCER RES, V57, P1841
[68]   APOPTOSIS IN CANCER-THERAPY - CROSSING THE THRESHOLD [J].
FISHER, DE .
CELL, 1994, 78 (04) :539-542
[69]   STUDIES ON MUTAGENESIS AND REPAIR INDUCED BY PLATINUM ANALOGS [J].
FRAM, RJ ;
CUSICK, PS ;
MARINUS, MG .
MUTATION RESEARCH, 1986, 173 (01) :13-18
[70]   INCREASED SENSITIVITY OF UV-REPAIR-DEFICIENT HUMAN CELLS TO DNA BOUND PLATINUM PRODUCTS WHICH UNLIKE THYMINE DIMERS ARE NOT RECOGNIZED BY AN ENDONUCLEASE EXTRACTED FROM MICROCOCCUS-LUTEUS [J].
FRAVAL, HNA ;
RAWLINGS, CJ ;
ROBERTS, JJ .
MUTATION RESEARCH, 1978, 51 (01) :121-132